<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449473</url>
  </required_header>
  <id_info>
    <org_study_id>D2210C00014</org_study_id>
    <nct_id>NCT02449473</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy &amp; Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids</brief_title>
  <acronym>MESOS</acronym>
  <official_title>A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Ph 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults With Asthma Inadequately Controlled on Inhaled Corticosteroid (MESOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2
      Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma
      Inadequately Controlled on Inhaled Corticosteroid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, randomized, double-blind, parallel group, placebo-controlled, phase 2
      study to designed evaluate the effect of a 300 mg dose of tralokinumab administered
      subcutaneously every 2 weeks on airway inflammation in adults with asthma inadequately
      controlled on inhaled corticosteroids (ICS) with or without other controllers. Approximately
      80 subjects will be randomized. Subjects will receive tralokinumab, or placebo, administered
      via subcutaneous injection at the study site, over a 12 week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2015</start_date>
  <completion_date type="Actual">June 21, 2017</completion_date>
  <primary_completion_date type="Actual">June 21, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway submucosal eosinophils</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>Change from baseline (expressed as a ratio) in number of airway submucosal eosinophiles per mm2 determined by microscopic evaluation of bronchoscopic biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood eosinophil count levels</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>Change from baseline (expressed as a ratio) in blood eosinophil count levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and sputum free eosinophil cationic protein (ECP) concentrations.</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>Change from baseline (expressed as a ratio) in blood and sputum free eosinophil cationic protein (ECP) concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Eosinophils</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>Change from baseline (expressed as a ratio) in number of differential sputum eosinophils.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability of tralokinumab assessed by the reporting of adverse events/serious adverse events.</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>To evaluate the safety and tolerability of tralokinumab</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety and Tolerability of tralokinumab assessed by the clinical chemistry/haemotology/urinanalysis parameters.</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>To evaluate the safety and tolerability of tralokinumab</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety and Tolerability of tralokinumab assessed by physical examinations/vital signs.</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>To evaluate the safety and tolerability of tralokinumab</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety and Tolerability of tralokinumab assessed by electrocardiogram.</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>To evaluate the safety and tolerability of tralokinumab</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tralokinumab Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tralokinumab Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose Regimen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Subcutaneous Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>Tralokinumab Dose Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>Placebo Dose Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 75 years

          2. Documented physician-diagnosed asthma for at least 12 months prior to enrolment (v1)

          3. Documented treatment with an asthma controller regimen requiring treatment with ICS
             (minimum dose of ≥ 250 ug fluticasone propionate via dry powder inhaler equivalents
             total daily dose) alone or in combination ≥ 6 months and that has been taken at a
             stable dose for at least 1 month prior to enrolment (v1)

          4. Additional maintenance asthma controller medications must be given at a stable dose
             for at least 1 month prior to v1.

          5. At enrolment (v1) the subject must have a predicted normal value (PNV) for the
             pre-bronchodilator (BD) FEV1&gt;50% and more than 1L.

          6. Post-BD reversibility in FEV1 of ≥12% and ≥200 mL at enrolment (v1).

        Exclusion Criteria:

          1. History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or
             other clinically significant lung disease other than asthma.

          2. History of anaphylaxis following any biologic therapy.

          3. Hepatitis B, C or HIV

          4. Pregnant or breastfeeding

          5. History of cancer

          6. Current tobacco smoking or a history of tobacco smoking for &gt;10 pack-years.

          7. Previous receipt of tralokinumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Brightling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Lung Health, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ålborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Århus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Reactive Airways</keyword>
  <keyword>Respiratory Tract Disease</keyword>
  <keyword>Obstructive Tract Disease</keyword>
  <keyword>Lung Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 23, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

